Effects of an Antioxidant Supplement on Blood Vessel Health

Part of paid clinical trials in Athens, Georgia.

Sponsor
University of Georgia
Study ID
NCT06424756
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • MitoQ — DIETARY_SUPPLEMENT
    MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
  • Placebo — DIETARY_SUPPLEMENT
    MitoQ matched Placebo
  • MitoTempo — DRUG
    During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
  • Tempol — DRUG
    During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
  • L-NAME — DRUG
    During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
  • SNP - Sodium Nitroprusside — DRUG
    At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.

Study Details

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.

Key Dates

Start date
Jul 1, 2024
Status verified
Dec 2024
Primary completion
Mar 31, 2030
Completion
Mar 31, 2030

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: MitoQ, then Placebo
    Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days
  • Experimental: Placebo, then MitoQ
    Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days

Primary Outcome Measure

Cutaneous microvascular responses to local heating [ Time Frame: 1 hour post intervention ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ramsey Student Center, University of GeorgiaAthensGeorgia30602-

Find similar trials in Athens, GA

By research site
Ramsey Student Center, University of Georgia· Athens, GA

Related Studies